A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

NCT03722823 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Tucatinib

Sponsor

Seagen Inc.